Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
It is not a question of follow the money, but follow the volume and then listen to what the company tells at AGM’ s etc.
Fiona McLaughlin’s presentation in Boston and what companies like Lilly is up to!
We got a company who I have always said it is the best thing out of Cambridge ( used to have office there) since ARM holdings.
There is a persistent buyer in the market and now will seriously have the majors stop taking no for an answer.
Avacta has told us once latest Cohort is out, next stop is a licensed deal and reorganise the company ( diagnostics) and we are off to the races.It is Friday, next week will heavy volume and suddenly no sellers. Classic situation! Seen it many times before, why do you think management have not been selling!
You have 30 min left and that will be the last time you can get in at these prices.Get on board and the trick is not to sell too early!!
Look at some of the US Biotech stocks and what happen to them.
Who can out bid most of the others ? JNJ is one of them.
Good luck, but buy now !!
Most of us must be up + 30% from the latest round and you will now look out for size lifting offer at 38, straight through 140, with a nice two hour Friday closing rally!
The trick is not to sell, too much happening and will happen.
Monday the Market will struggle to control the opening price and if you chaps knows anything about a fast moving market and bid price higher than offer, well that is what you will see next week.
It would be wise to get on board now or increase one’s holding. With next RNS being premier league, we will have a major Pharma joining the show and a complete re-rating of the company, with an avalanche of further highly price sensitive RNS’ being lined up.
140-5 for size, afternoon pre Monday trade could easily push us through 155-60 and get all the Chartist excited.
Let me explain what a working order is …
U.K. broker kicks off at normal pace with clear instructions and limits and once early team from NY is at their desk , they consult with London and move the buying up a gear or two. On NY holidays, the buyer operates from home, usual hours.
Will be very lively tomorrow.
If a NY based size buyer is buying in overseas market such as the U.K., then Thanksgiving Holliday and closure of the US market is irrelevant.
Will be a lively Friday with chart break out and perhaps even news-flow.
With upcoming Cohort news- License deal -Diagnostic disposal and potentially a major shareholder announcement in the very near future, if not over the next week or so, we will have an avalanche of price related news flow.Retail investors better step up the pace as substantial size buyers will run the show properly and with the usual MM’s on the bid continuing to front run the market,
The stock at this level is a gift you should take advantage of.
+ Look out for AVA3996 news.
Interesting to note that over the last couple of months, our chairman accepting another post as well.
Perhaps anticipating a US listing of the therapeutic business ( with the diagnostic business gone - page 15 AGM business review” future spin-out).
That off course will get the majors lined up !
Problems with link, cannot access the note!
More M&A in Biotech:
NEW YORK (Reuters) - Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical and has been in discussions with the biotechnology company for months about its future, according to two people familiar with the matter.
This should read well for PointBio and Lilly paying up and also nice read across to Avacta’s Affyxell!!